Do analysts rate CALT or INDV?

Indivior has a consensus price target of $45.17, indicating a potential upside of 17.41%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Indivior 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86

Do analysts rate MANE or CALT?

Veradermics currently has a consensus price target of $153.00, suggesting a potential upside of 38.19%. Given Veradermics' stronger consensus rating and higher probable upside, equities analysts plainly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradermics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer DFTX or CALT?

Definium Therapeutics presently has a consensus price target of $55.00, suggesting a potential upside of 21.82%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Definium Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Definium Therapeutics 1 Sell rating(s) 0 Hold rating(s) 15 Buy rating(s) 2 Strong Buy rating(s) 3.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate EWTX or CALT?

Edgewise Therapeutics currently has a consensus target price of $48.75, indicating a potential upside of 9.35%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer CALT or CPRX?

Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.62%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Catalyst Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.56

Calliditas Therapeutics AB (publ) (CALT) Competitors

$40.00 0.00 (0.00%)

As of 08/7/2026

Compare

CALT vs. INDV, MANE, DFTX, EWTX, and CPRX

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? Calliditas Therapeutics AB (publ)'s main competitors and comparable companies include Indivior (INDV), Veradermics (MANE), Definium Therapeutics (DFTX), Edgewise Therapeutics (EWTX), and Catalyst Pharmaceuticals (CPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Indivior (NASDAQ:INDV) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 0.7% of Indivior shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Indivior had 16 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 16 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.87 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Indivior	Positive

Indivior has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Indivior	$1.33B	3.41	$210M	$2.79	13.79

Indivior has a net margin of 26.65% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Indivior	26.65%	-283.11%	36.85%

Indivior has a consensus price target of $45.17, indicating a potential upside of 17.41%. Given Indivior's stronger consensus rating and higher probable upside, analysts plainly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Indivior	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Indivior has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 12 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Veradermics (NYSE:MANE) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

In the previous week, Veradermics had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Veradermics and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Veradermics' score of -0.21 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company	Overall Sentiment
Veradermics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Veradermics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Veradermics' return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.32	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Veradermics currently has a consensus price target of $153.00, suggesting a potential upside of 38.19%. Given Veradermics' stronger consensus rating and higher probable upside, equities analysts plainly believe Veradermics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Veradermics beats Calliditas Therapeutics AB (publ) on 8 of the 14 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Definium Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, Definium Therapeutics had 16 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 16 mentions for Definium Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Definium Therapeutics' score of -0.07 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company	Overall Sentiment
Definium Therapeutics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Definium Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Definium Therapeutics' return on equity of -84.01% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Definium Therapeutics presently has a consensus price target of $55.00, suggesting a potential upside of 21.82%. Given Definium Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Definium Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Definium Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Summary

Definium Therapeutics beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Edgewise Therapeutics currently has a consensus target price of $48.75, indicating a potential upside of 9.35%. Given Edgewise Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Edgewise Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Edgewise Therapeutics' return on equity of -39.01% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Edgewise Therapeutics had 18 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 18 mentions for Edgewise Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Edgewise Therapeutics' score of -0.24 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company	Overall Sentiment
Edgewise Therapeutics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Edgewise Therapeutics has a beta of 0.3, meaning that its share price is 70% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Edgewise Therapeutics beats Calliditas Therapeutics AB (publ) on 8 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Catalyst Pharmaceuticals?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.62%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Catalyst Pharmaceuticals and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Catalyst Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Catalyst Pharmaceuticals	Neutral

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Catalyst Pharmaceuticals has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Summary

Catalyst Pharmaceuticals beats Calliditas Therapeutics AB (publ) on 14 of the 16 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALT vs. The Competition

Export

Metric	Calliditas Therapeutics AB (publ)	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.19B	$11.95B	$7.06B	$12.95B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-21.62	788.51	269.75	24.74
Price / Sales	0.74	967.70	652.34	108.60
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	37.74	10.33	11.27	6.42
Net Income	-$43.96M	$2.77B	$3.45B	$347.12M
7 Day Performance	N/A	2.04%	3.56%	2.48%
1 Month Performance	N/A	-1.57%	-0.58%	-1.04%
1 Year Performance	N/A	191.33%	77.52%	23.22%

Calliditas Therapeutics AB (publ) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
INDV Indivior	3.7832 of 5 stars	$36.50 -2.3%	$45.67 +25.1%	+76.5%	$4.56B	$1.24B	18.72	1,051	Earnings Report Analyst Upgrade High Trading Volume
MANE Veradermics	2.2023 of 5 stars	$106.96 +5.0%	$153.00 +43.0%	N/A	$4.47B	N/A	N/A	19	Gap Down High Trading Volume
DFTX Definium Therapeutics	3.1709 of 5 stars	$42.32 +1.3%	$54.85 +29.6%	+368.4%	$4.17B	N/A	N/A	40	Earnings Report Analyst Forecast
EWTX Edgewise Therapeutics	1.9382 of 5 stars	$44.71 +16.5%	$48.75 +9.0%	+243.2%	$4.13B	N/A	N/A	60	News Coverage Positive News Earnings Report Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. INDV, MANE, DFTX, EWTX, and CPRX

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Summary

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Definium Therapeutics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Catalyst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. INDV, MANE, DFTX, EWTX, and CPRX

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Do institutionals and insiders hold more shares of CALT or INDV?

Does the media favor CALT or INDV?

Which has higher earnings and valuation, CALT or INDV?

Is CALT or INDV more profitable?

Do analysts rate CALT or INDV?

Which has more volatility and risk, CALT or INDV?

Summary

How does Calliditas Therapeutics AB (publ) compare to Veradermics?

Does the media prefer MANE or CALT?

Is MANE or CALT more profitable?

Which has higher valuation & earnings, MANE or CALT?

Do insiders and institutionals hold more shares of MANE or CALT?

Do analysts rate MANE or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Definium Therapeutics?

Which has more risk & volatility, DFTX or CALT?

Does the media favor DFTX or CALT?

Is DFTX or CALT more profitable?

Do insiders & institutionals believe in DFTX or CALT?

Do analysts prefer DFTX or CALT?

Which has preferable valuation and earnings, DFTX or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Do analysts rate EWTX or CALT?

Is EWTX or CALT more profitable?

Which has higher earnings & valuation, EWTX or CALT?

Does the media prefer EWTX or CALT?

Which has more risk and volatility, EWTX or CALT?

Do insiders and institutionals believe in EWTX or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Catalyst Pharmaceuticals?

Do analysts prefer CALT or CPRX?

Is CALT or CPRX more profitable?

Which has more risk & volatility, CALT or CPRX?

Does the media refer more to CALT or CPRX?

Do institutionals & insiders believe in CALT or CPRX?

Which has preferable earnings and valuation, CALT or CPRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools